Severe Hepatic Encephalopathy after the Transjugular Intrahepatic Portosystemic Shunt

Aim. To demonstrate a case of severe hepatic encephalopathy with focal neurological symptoms in the early postoperative period after transjugular intrahepatic portosystemic shunting (TIPS).

Key points. TIPS is the most common and effective pathogenetically justified shunting method for correcting portal hypertension in liver cirrhosis. The modern transplantology doctrine dictates an increasing need for TIPS as a bridge technology that improves patient survival on the liver transplant waiting list. The progression of hepatic encephalopathy in the postoperative period following this intervention is the main expected adverse consequence of the procedure. Timely diagnosis of worsening neuropsychiatric function in patients who have undergone TIPS and its effective restoration are pressing issues in contemporary gastroenterological practice. Screening examinations to detect hepatic encephalopathy should be regularly performed for all patients, who have undergone TIPS, regardless of the timing of the procedure. Complex therapy, including ornithine, lactulose, and antibacterial drugs to suppress excessive bacterial growth in the intestine, should be prescribed from the first days after the intervention. Since suppressing excessive bacterial growth in the intestine in patients with hepatic encephalopathy is an independent pathogenetically based therapeutic target, cyclical use of antibacterial agents for intestinal sanitation in patients with TIPS significantly enhances the effectiveness of controlling hepatic encephalopathy.

Conclusion. This case clearly demonstrates that the foundation of successful treatment for a patient with liver cirrhosis lies in the continuity and interconnection of all stages of care provision.

1. Ivashkin V.T., Mayevskaya M.V., Pavlov Ch.S., Fedosyina Ye.A. et al. Clinical guidelines of the Russian Scientific Liver Society and Russian gastroenterological association for the treatment of liver cirrhosis complications. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(4):71–102. (in Russian). DOI: 10.22416/1382-4376-2016-4-71-102

2. D’Amico G., Pasta L., Morabito A., D'Amico M. et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment. Pharmacol. Ther. 2014;39(10):1180–93. DOI: 10.1111/apt.12721

3. Fedosina E.A., Byeverov A.O., Bogomolov P.O., Staroverova N.P. Some practical issues in the management of patients with decompensated liver cirrhosis. Therapeutic Archive. 2019;91(8):148–54. (in Russian). DOI: 10.26442/00403660.2019.08.000391

4. De Martin E., Berg T., Samuel D., Berenguer M. et al. EASL Clinical Practice Guidelines on liver transplantation. J. Hepatol. 2024;81(6):1040–86. DOI: 10.1016/j.jhep.2024.07.032

5. Müller P.C., Kabacam G., Vibert E., Germani G. et al. Current status of liver transplantation in Europe. Int. J. Surg. 2020;82S:22–9. DOI: 10.1016/j.ijsu.2020.05.062

6. Kostrykin M.Yu. Development and justification of the liver transplant waiting list strategy: abstract of dr. med. theses. M.: National Medical Research Center for Transplantology and Artificial Organs named after Academician V.I. Shumakov; 2021. 179 p. (in Russian)

7. Zulkarnaev A.B. Features of survival analysis on patients on the "waiting list" for kidney transplantation. Bulletin of Siberian Medicine. 2020;18(2):215–22. (in Russian). DOI: 10.20538/1682-0363-2019-2-215-222

8. Minina M.G., Ignatov N.A., Truhmanov S.B. Mathematical аnalysis of kidney transplant demand and availability. Russian Journal of Transplantology and Artificial Organs. 2017;19(4):27–33. (in Russian). DOI: 10.15825/1995-1191-2017-4-27-33

9. Ritschl P.V., Wiering L., Dziodzio T., Jara M. et al. The effects of MELD-based liver allocation on patient survival and waiting list mortality in a country with a low donation rate. J. Clin. Med. 2020;9(6):1929. DOI: 10.3390/jcm9061929

10. Evans M.D., Diaz J., Adamusiak A.M., Pruett T.L. et al. Predictors of survival after liver transplantation in patients with the highest acuity (MELD ≥ 40). Ann. Surg. 2020;272(3):458–66. DOI: 10.1097/SLA.0000000000004211

11. Kim W.R., Lake J.R., Smith J.M., Schladt D.P. et al. OPTN/SRTR 2017 annual data report: liver. Am. J. Transplant. 2019;19(Suppl.2):184–283. DOI: 10.1111/ajt.15276

12. Metin O., Şimşek C., Gürakar A. Update on liver transplantation — newer aspects. Turk. J. Med. Sci. 2020;50(S1–2):1642–50. DOI: 10.3906/sag-2002-17

13. de Franchis R., Bosch J., Garcia-Tsao G., Reiberger T. et al. Baveno VII — Renewing consensus in portal hypertension. J. Hepatol. 2022;76(4):959–74. DOI: 10.1016/j.jhep.2021.12.022

14. Khoronko Yu.V., Kosovtsev E.V., Kozyrevsky M.A., Khoronko E.Yu. et al. Portosystemic shunting procedures for complicated portal hypertension: modern opportunities of miniinvasive technique. Annals of HPB Surgery. 2021;26(3):34–45. (in Russian). DOI: 10.16931/1995-5464.2021-3-34-45

15. Ivashkin V.T., Maevskaya M.V., Zharkova M.S., Zhigalova S.B. et al. Clinical recommendations of the Russian Scientific Liver Society and Russian Gastroenterological Association on Diagnosis and Treatment of Liver Fibrosis, Cirrhosis and Their Complications. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;6(31):56–102. (in Russiаn). DOI: 10.22416/1382-4376-2021-31-6-56-102

16. Montagnese S., Russo F.P., Amodio P., Burra P. et al. Hepatic encephalopathy 2018: a clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Dig. Liver Dis. 2019;51(2):190–205. DOI: 10.1016/j.dld.2018.11.035

17. Sharma P., Sharma B.C., Puri V., Sarin S.K. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. J. Hepatol. 2007;47(1):67–73. DOI: 10.1016/j.jhep.2007.02.022

18. Bajaj J.S. Management options for minimal hepatic encephalopathy. Expert Rev. Gastroenterol. Hepatol. 2008;2(6):785–90. DOI: 10.1586/17474124.2.6.785

19. Zipprich A., Garcia-Tsao G., Rogowski S., Fleig W.E. et al. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int. 2012;32(9):1407–14. DOI: 10.1111/j.1478-3231.2012.02830.x

20. Simonetti R.G., Perricone G., Robbins H.L., Battula N.R. et al. Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people e with cirrhosis. Cochrane Database Syst. Rev. 2020;10(10):CD000553. DOI: 10.1002/14651858.CD000553.pub3

21. Masson S., Mardini H.A., Rose J.D., Record C.O. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience. QJM. 2008;101(6):493–501. DOI: 10.1093/qjmed/hcn037

22. Dharel N., Bajaj J.S. Definition and nomenclature of hepatic encephalopathy. J. Clin. Exp. Hepatol. 2015;5(Suppl.1):S37–41. DOI: 10.1016/j.jceh.2014.10.001

23. Aitbaev K.A., Murkamilov I.T., Fomin V.V. Liver diseases: the pathogenetic role of the gut microbiome and the potential of therapy for its modulation. Therapeutic Archive. 2017;89(8):120–8. (in Russian). DOI: 10.17116/terarkh2017898120-128

24. Patidar K.R., Bajaj J.S. Antibiotics for the treatment of hepatic encephalopathy. Metab. Brain Dis. 2013;28(2):307–12. DOI: 10.1007/s11011-013-9383-5

25. Hudson M., Schuchmann M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. Eur. J. Gastroenterol. Hepatol. 2019;31(4):434–50. DOI: 10.1097/MEG.0000000000001311

26. Wang L.J., Yao X., Qi Q., Qin J.P. Prevention and treatment of hepatic encephalopathy during the perioperative period of transjugular intrahepatic portosystemic shunt. World J. Gastrointest. Surg. 2023;15(8):1564–73. DOI: 10.4240/wjgs.v15.i8.1564

27. Saad W.E. Portosystemic shunt syndrome and endovascular management of hepatic encephalopathy. Semin. Intervent. Radiol. 2014;31(3):262–5. DOI: 10.1055/s-0034-1382795

28. Rajesh S., George T., Philips C.A., Ahamed R. et al. Transjugular intrahepatic portosystemic shunt in cirrhosis: an exhaustive critical update. World J. Gastroenterol. 2020;26(37):5561–96. DOI: 10.3748/wjg.v26.i37.5561

29. Shabunin A.V., Bedin V.V., Drozdov P.A., Levina O.N. et al. First experience of transjugular intrahepatic portosystemic shunting at multidisciplinary hospital with a liver transplantation program. Annals of HPB Surgery. 2022;27(1):48–55. (in Russian). DOI: 10.16931/1995-5464.2022-1-48-55